Form 4: Kiniksa Pharmaceuticals Executive Awarded Performance-Based Equity

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, receives performance share units and options tied to the progress of KPL-387.

Summary

• John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, was granted performance share units (PSUs) and performance share options on May 1, 2025.
• The PSUs and options are contingent upon the achievement of specific performance criteria related to KPL-387, a treatment for recurrent pericarditis.
• 4,954 PSUs will vest upon submission of a biologics license application (BLA) to the FDA for KPL-387.
• An additional 5,201 PSUs will vest upon FDA approval for commercial sale and marketing of KPL-387 in the United States.
• 8,007 performance share options will vest upon submission of the BLA to the FDA.
• 8,266 performance share options will vest upon FDA approval for commercial sale and marketing of KPL-387 in the United States.
• The exercise price for the performance share options is $27.74, and they expire on April 30, 2035.
• The awards are subject to continued employment with the company, with certain exceptions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects standard executive compensation practices tied to key milestones. The success of KPL-387 is crucial for the value of these awards.

Positives

• The structure of the equity awards aligns management's interests with the successful development and commercialization of KPL-387.
• Achievement of the performance criteria (FDA submission and approval) could lead to significant value creation for the company and its shareholders.
• The long-term vesting schedule (until 2035 for options) encourages long-term commitment from the executive.

Risks

• Failure to achieve the performance criteria (FDA submission and approval) will result in the forfeiture of the PSUs and options.
• The value of the options is dependent on the share price exceeding the exercise price of $27.74.
• Continued employment is required for vesting, so any departure of the executive could impact the vesting of the awards.

Future Outlook

The future value of the PSUs and options is contingent on the successful development, regulatory approval, and commercialization of KPL-387.

Industry Context

Performance-based equity compensation is a common practice in the pharmaceutical industry to incentivize executives to achieve key milestones in drug development and commercialization. The focus on FDA milestones for KPL-387 reflects the critical importance of regulatory success in this sector.

Comparison to Industry Standards

• Many biotech companies use similar performance-based equity awards tied to clinical trial milestones, regulatory submissions, and approvals.
• The specific terms of the awards (e.g., vesting schedule, performance criteria) are typically tailored to the company's specific circumstances and the executive's role.
• Comparable companies like BioCryst Pharmaceuticals or Global Blood Therapeutics also utilize performance-based incentives for their executives.

Stakeholder Impact

• Shareholders benefit if KPL-387 is successfully developed and commercialized, as this would increase the company's value.
• Employees are impacted as the company's success can lead to job security and potential bonuses.
• Patients with recurrent pericarditis could benefit from a new treatment option if KPL-387 is approved.

Next Steps

• Kiniksa needs to successfully submit the biologics license application (BLA) to the FDA for KPL-387.
• Kiniksa needs to obtain FDA approval for the commercial sale and marketing of KPL-387 in the United States.

Key Dates

Keywords

Kiniksa Pharmaceuticals, John F. Paolini, Performance Share Units, Performance Share Options, KPL-387, FDA, Recurrent Pericarditis, Equity Awards, Vesting, Biologics License Application